CA3253889A1 - RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE - Google Patents
RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASEInfo
- Publication number
- CA3253889A1 CA3253889A1 CA3253889A CA3253889A CA3253889A1 CA 3253889 A1 CA3253889 A1 CA 3253889A1 CA 3253889 A CA3253889 A CA 3253889A CA 3253889 A CA3253889 A CA 3253889A CA 3253889 A1 CA3253889 A1 CA 3253889A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- independently
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22167670 | 2022-04-11 | ||
| EP22167670.3 | 2022-04-11 | ||
| PCT/EP2023/059154 WO2023198597A1 (en) | 2022-04-11 | 2023-04-06 | Rifabutin analogs for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3253889A1 true CA3253889A1 (en) | 2023-10-19 |
Family
ID=81306910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3253889A Pending CA3253889A1 (en) | 2022-04-11 | 2023-04-06 | RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250235434A1 (enExample) |
| EP (1) | EP4508053A1 (enExample) |
| JP (1) | JP2025513019A (enExample) |
| CN (1) | CN118974060A (enExample) |
| AU (1) | AU2023251806A1 (enExample) |
| CA (1) | CA3253889A1 (enExample) |
| WO (1) | WO2023198597A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025132358A1 (en) * | 2023-12-21 | 2025-06-26 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases |
| EP4696694A1 (en) | 2024-08-14 | 2026-02-18 | BioVersys AG | Antibiotic rifabutin analogs |
| EP4696695A1 (en) * | 2024-08-14 | 2026-02-18 | BioVersys AG | Antibiotic rifabutin analogs |
| WO2026062070A1 (en) * | 2024-09-18 | 2026-03-26 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of infectious diseases |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| PT102807A (pt) | 2002-07-09 | 2004-01-30 | Inst Nac De Engenharia E Tecno | Derivados n-substituidos de rifabutina uteis como agentes antimicrobianos, processo para a sua preparacao e sua utilizacao como medicamentos |
-
2023
- 2023-04-06 AU AU2023251806A patent/AU2023251806A1/en active Pending
- 2023-04-06 CA CA3253889A patent/CA3253889A1/en active Pending
- 2023-04-06 CN CN202380032448.9A patent/CN118974060A/zh active Pending
- 2023-04-06 JP JP2024559583A patent/JP2025513019A/ja active Pending
- 2023-04-06 EP EP23718239.9A patent/EP4508053A1/en active Pending
- 2023-04-06 WO PCT/EP2023/059154 patent/WO2023198597A1/en not_active Ceased
- 2023-04-06 US US18/855,839 patent/US20250235434A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118974060A (zh) | 2024-11-15 |
| EP4508053A1 (en) | 2025-02-19 |
| JP2025513019A (ja) | 2025-04-22 |
| WO2023198597A1 (en) | 2023-10-19 |
| US20250235434A1 (en) | 2025-07-24 |
| AU2023251806A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3253889A1 (en) | RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE | |
| EP3571189B1 (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| EP3571199B1 (en) | Bicyclic compounds as allosteric shp2 inhibitors | |
| WO2024165591A1 (en) | Rifabutin analogs for the treatment of bacterial diseases | |
| WO2024068926A1 (en) | Rifabutin analogs for the treatment of disease | |
| EP4452412B1 (en) | Rifabutin analogs for the treatment of disease | |
| WO2026037898A1 (en) | Antibiotic rifabutin analogs | |
| EP4469463B1 (en) | Rifamycin derivatives for the treatment of diseases | |
| EP4696694A1 (en) | Antibiotic rifabutin analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240904 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250206 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250206 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250218 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260318 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260318 |